hiv-1

Documents about hiv-1

• A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection#868894ClinicalTrials.gov
• The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine#844485ClinicalTrials.gov
• Genotypic and phenotypic characteristics of CXCR4-using transmitted/founder HIV-1 envelope glycoproteins#213127HAL (France)
• Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)#834363ClinicalTrials.gov
• Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1#841911ClinicalTrials.gov
• Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen#849326ClinicalTrials.gov
• Determination of HIV-1 Production by the Prostate#851893ClinicalTrials.gov
• Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection#855043ClinicalTrials.gov
• SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women#991901ClinicalTrials.gov
• PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)#1008405ClinicalTrials.gov
• Humoral immunity in HIV-1 post-treatment controllers#354035HAL (France)
• T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs#894010ClinicalTrials.gov
• A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection#668847ClinicalTrials.gov
• Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)#879235ClinicalTrials.gov
• Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients#896904ClinicalTrials.gov
• Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants#903388ClinicalTrials.gov
• Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis#915286ClinicalTrials.gov
• Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure#836627ClinicalTrials.gov
• A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults#904924ClinicalTrials.gov
• <b>Co-receptor usage in distinct phylogenetic clusters of HIV-1 CRF01_AE is associated with differential immune reconstitution after antiretroviral therapy</b>#329761Figshare
• Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1#332813ClinicalTrials.gov
• A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.#881344ClinicalTrials.gov
• Safer Conception Intervention for HIV-1 Serodiscordant Couples#1029847ClinicalTrials.gov
• Accelerating the development of affordable HIV drug resistance testing for use in low-and middle-income settings: report of a virtual meeting, 27 January 2025#155915WHO IRIS
• Scaling Up HIV Self‐Testing in Africa: Insights From National Programmatic Data in Eight Countries#147640HAL (France)
• A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)#840996ClinicalTrials.gov
• Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women#857025ClinicalTrials.gov
• Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women#872687ClinicalTrials.gov
• The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects#875463ClinicalTrials.gov
• TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients#859109ClinicalTrials.gov
• Reducing Antiretroviral Treatments#913695ClinicalTrials.gov
• Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs#828540ClinicalTrials.gov
• Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults#623543ClinicalTrials.gov
• Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection#881573ClinicalTrials.gov
• Characterization of HIV-1 virus-like particles and determination of Gag stoichiometry for different production platforms.#372166Repisalud
• A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab#624810HAL (France)
• Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption#826420ClinicalTrials.gov
• Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)#916494ClinicalTrials.gov
• Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults#172389ClinicalTrials.gov
• Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients#208268ClinicalTrials.gov
• Influence of the intracellular environment on HIV-1 replication and its modulation by innate cytokines#228155Ora Oxford University Research
• A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine#432931ClinicalTrials.gov
• An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection#805026ClinicalTrials.gov
• Effect of Cenicriviroc on HIV Neurocognitive Impairment#826061ClinicalTrials.gov
• Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen#841789ClinicalTrials.gov
• Maraviroc Immune Recovery Study#861025ClinicalTrials.gov
• Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients#898679ClinicalTrials.gov
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients#1030393ClinicalTrials.gov
• Table 1_HIV-1 molecular transmission networks among MSM in Ningxia, China (2018–2024): insights into local transmission dynamics and drug resistance.docx#266440Figshare
• Presentation 1_HIV-1 molecular transmission networks among MSM in Ningxia, China (2018–2024): insights into local transmission dynamics and drug resistance.pptx#266441Figshare